Assessment of the Classification of Age-Related Macular Degeneration Severity from the Northern Ireland Sensory Ageing Study Using a Measure of Dark Adaptation.
AMD, age-related macular degeneration
AdaptDx
Age-related macular degeneration
Beckman
CFP, color fundus photography
OCT-based grading
RIT, rod-intercept time
RMDA, rod-mediated dark adaptation
RPE, retinal pigment epithelium
Rod-mediated dark adaptation
SD-OCT, spectral-domain OCT
SDD, subretinal drusenoid deposit
VA, visual acuity
iAMD, intermediate age-related macular degeneration
Journal
Ophthalmology science
ISSN: 2666-9145
Titre abrégé: Ophthalmol Sci
Pays: Netherlands
ID NLM: 9918230896206676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
16
11
2021
revised:
27
05
2022
accepted:
12
07
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
To assess the differences in rod-mediated dark adaptation (RMDA) between different grades of age-related macular degeneration (AMD) severity using an OCT-based criterion compared with those of AMD severity using the Beckman color fundus photography (CFP)-based classification and to assess the association between the presence of subretinal drusenoid deposits (SDDs) and RMDA at different grades of AMD severity using an OCT-based classification. Cross-sectional study. Participants from the Northern Ireland Sensory Ageing study (Queen's University Belfast). Complete RMDA (rod-intercept time [RIT]) data, CFP, and spectral-domain OCT images were extracted. Participants were stratified into 4 Beckman groups (omitting late-stage AMD) and 3 OCT-based groups. The presence and stage of SDDs were identified using OCT. Rod-intercept time data (age-corrected). Data from 459 participants (median [interquartile range] age, 65 [59-71] years) were stratified by both the classifications. Subretinal drusenoid deposits were detected in 109 eyes. The median (interquartile range) RMDA for the Beckman classification (Beckman 0-3, with 3 being intermediate age-related macular degeneration [iAMD]) groups was 6.0 (4.5-8.7), 6.6 (4.7-10.5), 5.7 (4.4-7.4), and 13.2 (6-21.1) minutes, respectively. OCT classifications OCT0-OCT2 yielded different median (interquartile range) values: 5.8 (4.5-8.5), 8.4 (5.2-13.3), and 11.1 (5.3-20.1) minutes, respectively. After correcting for age, eyes in Beckman 3 (iAMD) had statistically significantly worse RMDA than eyes in the other Beckman groups ( Eyes with a structural definition of iAMD have delayed RMDA, regardless of whether a CFP- or OCT-based criterion is used. In this study, after correcting for age, the RMDA did not differ between groups of eyes defined to have early AMD or normal aging, regardless of the classification. The presence of SDDs has some effect on RMDA at different grades of AMD severity.
Identifiants
pubmed: 36531574
doi: 10.1016/j.xops.2022.100204
pii: S2666-9145(22)00093-8
pmc: PMC9754971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100204Informations de copyright
© 2022 by the American Academy of Ophthalmology.
Références
Ophthalmology. 2019 Jun;126(6):856-865
pubmed: 30278196
Ophthalmologica. 2019;241(2):61-72
pubmed: 30153664
Invest Ophthalmol Vis Sci. 1994 May;35(6):2857-64
pubmed: 8188481
BMJ Open. 2016 Dec 2;6(12):e011504
pubmed: 27913556
Biomed Opt Express. 2017 Jun 23;8(7):3440-3448
pubmed: 28717579
Retina. 2017 Jul;37(7):1329-1336
pubmed: 28633153
Br J Ophthalmol. 2011 Oct;95(10):1427-32
pubmed: 21289019
Invest Ophthalmol Vis Sci. 2014 May 22;55(8):4776-89
pubmed: 24854857
Ophthalmology. 2010 Feb;117(2):303-12.e1
pubmed: 19815280
Retina. 2021 Aug 1;41(8):1715-1722
pubmed: 33411474
Sci Rep. 2021 Apr 15;11(1):8323
pubmed: 33859209
Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1551-1558
pubmed: 28534244
Transl Vis Sci Technol. 2017 Jun 05;6(3):15
pubmed: 28593103
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD114-AMD121
pubmed: 30105357
Surv Ophthalmol. 2018 Nov - Dec;63(6):782-815
pubmed: 29859199
Am J Ophthalmol. 2018 May;189:127-138
pubmed: 29477964
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):739-45
pubmed: 26906160
Ophthalmology. 1991 Jul;98(7):1128-34
pubmed: 1843453
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1782-9
pubmed: 27074381
Invest Ophthalmol Vis Sci. 2014 Mar 10;55(3):1427-31
pubmed: 24550363
Am J Ophthalmol. 2016 May;165:65-77
pubmed: 26940163
Curr Eye Res. 2016;41(2):266-72
pubmed: 25802989
Ophthalmol Retina. 2020 Mar;4(3):274-283
pubmed: 31924545
Biomed Opt Express. 2014 Sep 12;5(10):3568-77
pubmed: 25360373
J Ocul Biol Dis Infor. 2008 Mar;1(1):7-11
pubmed: 20072631
Ophthalmology. 2014 Jan;121(1):162-172
pubmed: 23993787
Invest Ophthalmol Vis Sci. 2013 Apr 03;54(4):2429-34
pubmed: 23471895
Ophthalmol Ther. 2021 Mar;10(1):21-38
pubmed: 33565038
Ophthalmology. 2017 Sep;124(9):1340-1352
pubmed: 28501377
Ophthalmology. 2015 Oct;122(10):2053-62
pubmed: 26253372
Am J Ophthalmol. 2018 Jun;190:113-124
pubmed: 29621510
Transl Vis Sci Technol. 2020 Dec 15;9(2):62
pubmed: 33344065
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4838-4848
pubmed: 31747683
Ophthalmology. 2014 Jun;121(6):1252-6
pubmed: 24518615
Prog Retin Eye Res. 2004 May;23(3):307-80
pubmed: 15177205
Retina. 2010 Oct;30(9):1441-54
pubmed: 20924263
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):267-73
pubmed: 10634630
Exp Eye Res. 2022 Jan;214:108882
pubmed: 34890604
Neuron. 2012 Jul 12;75(1):26-39
pubmed: 22794258
Health Technol Assess. 2016 Oct;20(80):1-120
pubmed: 27809956
Ophthalmol Retina. 2020 Nov;4(11):1059-1068
pubmed: 32389889
Ophthalmology. 2008 Nov;115(11):1883-90
pubmed: 18722666
Retina. 2013 Feb;33(2):265-76
pubmed: 23266879
Surv Ophthalmol. 1995 Mar-Apr;39(5):367-74
pubmed: 7604360
Vision Res. 1999 Nov;39(23):3975-82
pubmed: 10748929
Ophthalmology. 2016 May;123(5):1090-100
pubmed: 26875000
Ophthalmology. 2016 Feb;123(2):344-351
pubmed: 26522707